Evidence map›Paper›PMID 39289942›Full record

ArticleCombinatorial chemistry & high throughput screening2025

Investigation of the Mechanism of Siweixizangmaoru Decoction in Improving CIA-Induced Arthritis in Rats Based on Network Pharmacology and Experimental Verification.

Yanfei Niu, Yanxiang Yuan, Tong Wang, Ruiying Yuan, Min Zhang, Sicen Wang, Dikye Tsering, Shan Huang, Bin Li

Abstract read
PubMed Publisher
In one paragraph

Article in Combinatorial chemistry & high throughput screening, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanfei NiuDepartment of Pharmaceutical Engineering and Pharmaceutical Chemistry, School of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, 266042, China.
Yanxiang YuanDepartment of Pharmaceutical Engineering and Pharmaceutical Chemistry, School of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, 266042, China.
Tong WangDepartment of Pharmaceutical Engineering and Pharmaceutical Chemistry, School of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, 266042, China.
Ruiying YuanDepartment of Pharmacy, College of Medicine, Tibet University, Lhasa, 850000, China.
Min ZhangState Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Sicen WangDepartment of Pharmacy, College of Medicine, Tibet University, Lhasa, 850000, China.
Dikye TseringDepartment of Tibetan Medicine, College of Medicine, University of Tibetan Medicine, Lhasa, 850007, China.
Shan HuangDepartment of Pharmaceutical Engineering and Pharmaceutical Chemistry, School of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, 266042, China.
Bin LiDepartment of Pharmaceutical Engineering and Pharmaceutical Chemistry, School of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, 266042, China.

Funding

National Natural Science Foundation of China 82074578, 81960775Shandong Provincial Natural Science Foundation ZR2021LZY032
6 · The paper itself

Abstract

backgroundRheumatoid Arthritis (RA) is a chronic autoimmune disease with a complex etiology. Siweixizangmaoru Decoction (SXD) has been used to treat RA in Tibet for a long history as a classic Tibetan medicine formula. However, the potential pharmacological mechanism has not been elucidated yet.

aimsThe aim of this study was to evaluate the efficacy and mechanism of action of SXD in the treatment of RA using network pharmacology and molecular docking analysis.

methodsNetwork pharmacology was employed to identify the potential bioactive components and key targets of SXD for the treatment of RA. Molecular docking of key targets and potential compounds was conducted. High-performance liquid chromatography was performed to validate the predicted active components of SXD. We established a rat model of RA and evaluated the histopathology of each group of rats. In addition, the levels of inflammatory factors in serum and the expression levels of PI3K/AKT and MAPK pathway-related proteins in synovial tissue were detected.

resultsThe results of network pharmacological analyses indicated that apigenin, rhamnolipids, kaempferol, quercetin, and naringenin are potential bioactive components of SXD for the treatment of rheumatoid arthritis and that their therapeutic effects may be related to the PI3K-Akt and MAPK pathways. The results of in vivo experiments show that SXD improved the arthritis index, significantly reduced joint swelling, and improved synovial inflammation and cartilage destruction.

conclusionNetwork pharmacology, along with experimental validation, provided a useful approach for understanding the pharmacological mechanism of Siweixizangmaoru decoction in RA.

Indexed as

Arthritis, ExperimentalArthritis, RheumatoidDrugs, Chinese HerbalNetwork PharmacologyAnimalsMaleMolecular Docking SimulationRatsRats, Sprague-DawleyDrugs, Chinese Herbalmolecular dockingnetwork pharmacologyPI3K-Akt/MAPK signaling pathwayrheumatoid arthritisSiweixizangmaoru decoctiontibetan medicine formula.

Identifiers

PMID39289942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.